PwC’s 6. Schweizer MWST-Tagung

Die Mehrwertsteuer, insbesondere im Pharma Bereich für Konzerne, KMUs und Start-ups, ist im steten Wandel und immer transparenter.

Für Sie als Entscheidungsträger im Pharma & Life Sciences Bereich, wird es immer schwieriger all die gesetzlichen und behördlichen Vorgaben / Neuerungen effizient und kostengünstig einzuhalten. Dazu kommt die anhaltende COVID-19-Situation, welche umsatzsteuerliche Herausforderungen mit sich bringt und die es zu meistern gilt. Gleichzeitig spielt Industrie 4.0 und die umfassende Digitalisierung in der industriellen Produktion eine immer wichtigere Rolle. Dieser absehbare Wandel bringt neue Chancen zur Prozessoptimierung.

Continue reading PwC’s 6. Schweizer MWST-Tagung

Webinar: How can ESG create value in the pharma industry?

ESG stands for ‘environmental, social and governance’ – without a doubt a global mega trend, and even more so in the post Covid-19 world.

During this webinar, we will look at how a strong ESG proposition can create value. In particular, we will illustrate the value creation process by providing a framework tailored to the pharma value chain to describe the various options.

Continue reading Webinar: How can ESG create value in the pharma industry?

Trade obstacles for MedTech companies due to the failed negotiations on the EU-Switzerland Institutional Agreement

Switzerland and the EU did not reach a consensus on the negotiations of the Institutional Framework Agreement. As a consequence, the Mutual Recognition Agreement (MRA) between the EU and Switzerland and related provisions for medical devices were not updated and, therefore, ceased to apply on 26 May 2021. With that, as of now Switzerland is considered as a ‘third country’ and Swiss MedTech companies lost their previously barrier-free access to the EU market and vice versa. The following article shows what companies selling medical devices need to consider when exporting to the EU or Switzerland.

Continue reading Trade obstacles for MedTech companies due to the failed negotiations on the EU-Switzerland Institutional Agreement

WEBINAR – Pharma news: German court decision – Sale of drugs from a Swiss company and new EU requirements

Dear pharma members

Germany has recently published a court decision with major impact on the pharma supply chain (commercial and clinical) in the EU Member States:

Continue reading WEBINAR – Pharma news: German court decision – Sale of drugs from a Swiss company and new EU requirements

Webinar – Global Indirect Tax Health Industry Convention, 6 May 2021 2pm–6pm CEST

We are delighted to invite you to our virtual Global Indirect Tax Health Industry Convention “Succeeding through uncertainty” on Thursday 6 May 2021 from 2pm to 6pm CEST. We will discuss the latest hot topics in the pharma, healthcare and life science industry from an indirect tax perspective and beyond.

The incredible pace of change in indirect taxes in the pharma, healthcare and life sciences industry shows no sign of slowing down. Digital transformation, changes in supply chains due to the pandemic, Brexit and complex developments in EU legislation are just some of the factors that are currently having a major impact on this industry and affecting almost every aspect of our business lives.

Continue reading Webinar – Global Indirect Tax Health Industry Convention, 6 May 2021 2pm–6pm CEST

VAT refund due to taxpayer on pharmaceutical rebates

The Dutch Court of First Instance has found in favour of the taxpayer in a case involving indirect rebates paid to pharmaceutical companies. In essence, the court granted a refund of VAT to a pharmaceutical company based on the CJEU Boehringer case (C-462/16), although the pharmaceutical company was not obliged to grant the rebates under national law. Although the case was concerned with price arrangements with the Minister of Health, Welfare and Sport, it is possible that the same rationale could be applied to other rebate schemes, such as rebate arrangements between pharmaceutical companies and insurance companies.

Continue reading VAT refund due to taxpayer on pharmaceutical rebates

Webinar – After the Brexit deal: what you need to know and do next – 18 January, 9am

The Brexit transition period ended on 31 December 2020 and there is finally a deal between the United Kingdom and the European Union. However, many relevant practical questions for businesses remain open and still need to be resolved especially in the Pharma & Life Sciences sector.

Continue reading Webinar – After the Brexit deal: what you need to know and do next – 18 January, 9am

EU Commission welcomes agreement on crucial VAT relief for COVID-19 vaccines and testing kits

The EU Commission has adopted a proposal, allowing the EU Member States to apply a zero rate VAT rate on Covid-19 vaccines and testing products. Currently, Member States can apply reduced VAT rates on sales of vaccines, but cannot apply a zero rate, while testing kits cannot benefit from reduced rates. As a consequence, different EU Member States might be adopting such a zero/reduced rate in the next coming months for these products (they are not obliged to).

Continue reading EU Commission welcomes agreement on crucial VAT relief for COVID-19 vaccines and testing kits

The impact of Brexit on Pharma, Life Science and MedTech companies – A PwC Pharma & Life Sciences Webinar

Dear pharma & life sciences colleagues

Brexit is coming closer every day with many aspects still unclear which makes it hard for you to prepare for it.

We’re excited to take a closer look at the current status quo and the impact of Brexit on indirect taxes, movement of goods and trade for Pharma, Life Sciences and MedTech Companies.

Continue reading The impact of Brexit on Pharma, Life Science and MedTech companies – A PwC Pharma & Life Sciences Webinar